Mutual fund investors who wish to make the most of this growth of the anti-viral drug therapy market can consider a few funds that invest in companies that are currently working in the arena of antiviral drug therapy.

The top ten mutual funds that performed in the first half are highlighted.

Looking at the mutual funds, the healthcare mutual funds were once again the best gainers among the sector equity funds. Its robust 10.7% return in Q1 was far above the second-placed Real Estate sector’s return of about 4.4%.